Interventional Cardiology Market

Abbott Laboratories held 21% of the $18.5B market at close of 2025, pulling ~$3.9B in sector revenue by our count. Boston Scientific sat at 18% ($3.3B), Medtronic plc at 15% ($2.8B), and Edwards Lifesciences at 10% ($1.85B). The top four control 64% of the field. Coronary stents. Abbott's Xience and Boston's Synergy platforms, accounted for 35% of total market value. The remainder split across catheters (28%) and guidewires (18%), both heavily commoditized outside the top-tier operators.

North America held 46% of the base, Europe 28%, and Asia Pacific 22% as measured by Grand View Research in early 2025. Percutaneous coronary intervention (PCI) drove 52% of procedure volume, TAVR 25%, and electrophysiology 23%. The TAVR figure is up 400 basis points year-on-year on Edwards and Medtronics expanded indications into intermediate-risk cohorts. We saw CMS approve broader TAVR coverage in Q4 2024, which is compounding through hospital adoption now.

Boston Scientific is taking share in both PCI and EP after the Farapulse acquisition closed in January 2024. Abbott isn't sitting still, our desk tracked the Amulet left atrial appendage occluder gaining traction in European centres where oral anticoagulation isn't tolerated. Medtronic plc's Evolut TAVR platform is the volume leader in Asia Pacific, where transcatheter adoption lags the West by three to five years. That lag is the opportunity. Generic drug-eluting stents out of China and India are pricing 60–70% below Abbott and Boston in emerging markets, eroding margin but not yet volume for the incumbents.

Reimbursement cuts break the thesis. CMS floated a 3% reduction to PCI bundled payments in the proposed 2026 rule; if that lands, hospital systems will push back on premium devices and Abbott's pricing power weakens. TAVR economics depend on expanding into low-risk aortic stenosis patients, but the PARTNER 3 and Evolut Low Risk trials showed only modest benefit over surgery in that cohort, payers could balk. Generic DES platforms from MicroPort and Lepu Medical are improving fast; if they pass FDA scrutiny and enter the U.S. under a streamlined 510(k), the stent oligopoly cracks. We're also watching for adverse event signals in the post-market registries, any uptick in late stent thrombosis or valve migration would stall procedural growth.